Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830621 | 0.90 | MAOB (0.52) | LMNAHIF1AALDH1A1HTR7BRD9 | |
| SCHEMBL27722423 | 0.87 | DPP4 (0.46) | LMNAHIF1AALDH1A1BRD9CYP2C9 | |
| SCHEMBL17893697 | 0.85 | HTR2C (0.44) | HIF1AALDH1A1 | |
| SCHEMBL17893825 | 0.85 | KDM4E (0.46) | LMNAHIF1AALDH1A1HTR7 | |
| SCHEMBL7492716 | 0.85 | MAOB (0.44) | LMNAHIF1AALDH1A1SIRT6PKM | |
| SCHEMBL3228974 | 0.85 | MAPT (0.49) | LMNAALDH1A1 | |
| SCHEMBL17893801 | 0.85 | LMNA (0.47) | LMNAHIF1AALDH1A1SIRT6PKM | |
| SCHEMBL310030 | 0.85 | ALDH1A1 (0.47) | LMNAHIF1AALDH1A1SIRT6PKM | |
| SCHEMBL16432036 | 0.85 | ALDH1A1 (0.47) | LMNAHIF1AALDH1A1SIRT6MEN1 | |
| SCHEMBL17901911 | 0.84 | HTR2C (0.43) | LMNAHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| CN-107108610-B | Novel tetrahydropyridopyrimidine and tetrahydropyridopyridine compounds for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3240537-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-10-19 | — | — | US | disclosed |
| CN-107108610-A | Novel tetrahydropyridopyrimidine and tetrahydropyridopyridine compounds for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20100087485-A1 | 4-AMINOPIPERIDINE DERIVATIVES | BOEHRINGER MARKUS | 2010-04-08 | — | — | US | disclosed |
| US-7683079-B2 | 4-aminopiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-23 | — | — | US | disclosed |
| CN-101090888-A | 4-aminopiperidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | CN | disclosed |
| EP-1831165-A1 | 4-AMINOPIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066747-A1 | 4-AMINOPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135561-A1 | 4-Aminopiperidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-06-22 | — | — | US | disclosed |
| EP-1146871-A4 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1146871-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6225324-B1 | POTENT INHIBITION OF 5-HT REUPTAKE; 1,3-DISUBSTITUTED PYRROLIDINE, 1,4-DISUBSTITUTED PIPERIDINE, OR 1,4-DISUBSTITUTED HEXAHYDROAZEPINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2000044376-A1 | ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087485-A1 | 4-AMINOPIPERIDINE DERIVATIVES | DPP4, GPR119, IAPP | LMNA 4349/4885HIF1A 3288/4885ALDH1A1 199/4885 |
| US-20170298067-A1 | NOVEL TETRAHYDROPYRIDOPYIMIDINES AND TETRAHYDROPRIDOPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPX2, QDPR, TPMT | LMNA 3590/4885HIF1A 3977/4885ALDH1A1 2832/4885 |
| US-20060135561-A1 | 4-Aminopiperidine derivatives | DPP4, GPR119, IAPP | LMNA 4349/4885HIF1A 3288/4885ALDH1A1 199/4885 |
| US-10196391-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | TPMT, TYMP, DPYD | LMNA 3353/4885HIF1A 3431/4885ALDH1A1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.